Literature DB >> 32130578

Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis.

Ran Wang1, Ting Li2, Shuang Ye2, Wenfeng Tan3, Cheng Zhao4, Yisha Li5, Chun de Bao6, Qiong Fu7.   

Abstract

OBJECTIVES: To explore the clinical features, treatments, and prognostic factors of adult-onset Still's disease (AOSD)-associated macrophage activation syndrome (MAS), we conducted a multicenter retrospective clinical study of AOSD-associated MAS patients.
METHODS: AOSD patients were collected from six tertiary hospitals in China. Medical charts were reviewed and clinical information was recorded and analyzed.
RESULTS: There were 447 AOSD patients enrolled into this retrospective clinical study. Among them, 55 were diagnosed with MAS. Liver dysfunction was the most reliable predictive factor for the screening of MAS in AOSD patients (OR = 75.744, 95%CI = 23.015-249.284, p < 0.0001). In multivariate analysis, clinical features including platelets < 100 × 109/L (OR = 9.546, p = 0.005), aspartate transaminase (AST) > 120 U/L (OR = 25.853, p < 0.0001), triglycerides > 3 mmol/L (OR = 12.9833, p = 0.011)), ferritin > 1500 ng/mL (OR = 5.513, p = 0.050), as well as hemophagocytosis in bone puncture (OR = 18.132, p = 0.001) were highly associated with the occurrence of MAS. The mortality rate of total AOSD patients was 4.47%, MAS was the main cause of death in AOSD patients (OR = 11.705, 95%CI = 4.783-28.647, p < 0.0001). PLT ≤ 100 × 109/L (p = 0.0001), fibrinogen < 1.5 g/L (p = 0.0286), splenomegaly (p = 0.0002), and liver dysfunction (p = 0.0008) highly suggested poor prognosis.
CONCLUSION: MAS occurrence is the major cause of death in AOSD patients. Notable liver dysfunction, as well as splenomegaly, low number of platelets or neutrophils, high levels of serum ferritin, and reduced level of fibrinogen are risk factors for poor outcome. Key Points • This is a multicenter retrospective study of AOSD-associated MAS with large number of cases.

Entities:  

Keywords:  Adult-onset Still’s disease; Macrophage activation syndrome; Treatment

Mesh:

Substances:

Year:  2020        PMID: 32130578     DOI: 10.1007/s10067-020-04949-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  Extremely High Ferritinemia Associated with Haemophagocytic Lympho Histiocytosis (HLH).

Authors:  Neelima Verma; Jyoti Chakraverty; Pankaj Baweja; Alka Girotra; Leena Chatterjee; Manish Chugh
Journal:  Indian J Clin Biochem       Date:  2016-02-17

2.  Adult onset Still's disease accompanied by acute respiratory distress syndrome: A case report.

Authors:  Xiao-Tu Xi; Mao-Jie Wang; Run-Yue Huang; Bang-Han Ding
Journal:  Exp Ther Med       Date:  2016-07-11       Impact factor: 2.447

3.  Adult Still's disease--recognition of a clinical syndrome and recent experience.

Authors:  E B Larson
Journal:  West J Med       Date:  1985-05

Review 4.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Annu Rev Med       Date:  2014-11-05       Impact factor: 13.739

Review 5.  Adult-onset Still's disease: current challenges and future prospects.

Authors:  Mariam Siddiqui; Michael S Putman; Anisha B Dua
Journal:  Open Access Rheumatol       Date:  2016-03-15

6.  Adult Onset Still's Disease Associated with Mycoplasma pneumoniae Infection and Hemophagocytic Lymphohistiocytosis.

Authors:  Abhishek Agnihotri; Allison Ruff; Lauren Gotterer; Addie Walker; Amy H McKenney; Andrei Brateanu
Journal:  Case Rep Med       Date:  2016-10-26

Review 7.  Parenchymal lung involvement in adult-onset Still disease: A STROBE-compliant case series and literature review.

Authors:  Mathieu Gerfaud-Valentin; Vincent Cottin; Yvan Jamilloux; Arnaud Hot; Agathe Gaillard-Coadon; Isabelle Durieu; Christiane Broussolle; Jean Iwaz; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

8.  Adult onset Still's disease with dermatopathic lymphadenopathy.

Authors:  Ahmad Z Qureshi; Mohammad AlSheef; Waqas T Qureshi; Waseem Amjad
Journal:  Saudi Med J       Date:  2016-11       Impact factor: 1.484

Review 9.  Adult-Onset Still's Disease: Still a Serious Health Problem (a Case Report and Literature Review).

Authors:  Mojgan Agha-Abbaslou; Ana Maria Bensaci; Oluchi Dike; Mark C Poznansky; Arooj Hyat
Journal:  Am J Case Rep       Date:  2017-02-03

10.  Pulmonary involvement in adult Still's disease: Case report and brief review of literature.

Authors:  Aldo Guerrieri; Giulia Angeletti; Massimiliano Mazzolini; Ilaria Bassi; Stefano Nava
Journal:  Respir Med Case Rep       Date:  2017-07-03
View more
  11 in total

1.  The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.

Authors:  Kuo-Tung Tang; Chia-Wei Hsieh; Hsin-Hua Chen; Yi-Ming Chen; Shih-Hsin Chang; Po-Hao Huang; Joung-Liang Lan; Der-Yuan Chen
Journal:  Clin Rheumatol       Date:  2021-09-17       Impact factor: 2.980

2.  Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.

Authors:  Ran Wang; Ting Li; Shuang Ye; Liangjin Lv; Sheng Chen; Xiaodong Wang; Chun-de Bao; Qiong Fu
Journal:  Clin Rheumatol       Date:  2022-05-19       Impact factor: 3.650

Review 3.  Progress in Biological Therapies for Adult-Onset Still's Disease.

Authors:  Paola Galozzi; Sara Bindoli; Andrea Doria; Paolo Sfriso
Journal:  Biologics       Date:  2022-04-21

4.  Acute liver injury in a patient with adult-onset Still's disease-the challenge of differential diagnosis.

Authors:  Sabine Weber; Alexander L Gerbes
Journal:  Oxf Med Case Reports       Date:  2020-11-24

5.  Total metabolic lesion volume of lymph nodes measured by 18F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still's disease.

Authors:  Liyan Wan; Yuting Gao; Jieyu Gu; Huihui Chi; Zhihong Wang; Qiongyi Hu; Jinchao Jia; Tingting Liu; Biao Li; Jialin Teng; Honglei Liu; Xiaobing Cheng; Junna Ye; Yutong Su; Chengde Yang; Hui Shi; Min Zhang
Journal:  Arthritis Res Ther       Date:  2021-03-30       Impact factor: 5.156

6.  Latent class analysis of 216 patients with adult-onset Still's disease.

Authors:  Takahiro Sugiyama; Shunsuke Furuta; Masaki Hiraguri; Kei Ikeda; Yosuke Inaba; Shin-Ichiro Kagami; Yasuhiko Kita; Kei Kobayashi; Yoshihisa Kobayashi; Kazuhiro Kurasawa; Daiki Nakagomi; Yasushi Nawata; Yohei Kawasaki; Yuki Shiko; Takao Sugiyama; Hiroshi Nakajima
Journal:  Arthritis Res Ther       Date:  2022-01-03       Impact factor: 5.156

7.  Detection and Prediction of Macrophage Activation Syndrome in Still's Disease.

Authors:  Clément Javaux; Thomas El-Jammal; Pierre-Antoine Neau; Nicolas Fournier; Mathieu Gerfaud-Valentin; Laurent Perard; Marine Fouillet-Desjonqueres; Julie Le Scanff; Emmanuelle Vignot; Stéphane Durupt; Arnaud Hot; Alexandre Belot; Isabelle Durieu; Thomas Henry; Pascal Sève; Yvan Jamilloux
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

Review 8.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

Review 9.  Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.

Authors:  Serena Colafrancesco; Rossana Scrivo; Cristiana Barbati; Fabrizio Conti; Roberta Priori
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

Review 10.  COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.

Authors:  Periklis Vounotrypidis
Journal:  Mediterr J Rheumatol       Date:  2020-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.